Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment

Inclusion Criteria:

* Patients must have metastatic colorectal cancer.
* Patients must have at least one measurable lesion.
* Patients'serum level of CEA must be higher than 5 times of the normal value
* Patients'disease must have failed chemotherapy with 5FU, CPT-11 or oxaliplatin.
* Patients who are unsuitable or refuse chemotherapy will be considered eligible for this trial.
* Patients'age must be 20 or greater.
* Patients'estimated life expectancy is more than 3 months.
* Patients must have adequate bone marrow function, defined as WBC \>= 3500/mm3, neutrophil \>= 1500/mm3, lymphocyte \>= 1,000/mm3, and platelet \>= 100,000/mm3.
* Patients must have adequate liver and renal function, defined as serum alanine transaminase (ALT) and aspartate transaminase (AST) =\< 5 times normal, bilirubin =\< 1.5 times normal range, and creatinine =\< 2 times upper normal limit.
* All patients should have documentation of negative result of penicillin test.
* Women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
* All patients must be informed of the investigational nature of this study and must sign and give written informed consent.

Exclusion Criteria:

* Patients who have central nervous system metastasis except for those whose CNS disease has been treated with radiotherapy and/or surgery and has been stable for at least two weeks
* Patients who have active acute or chronic infection (at the discretion of the investigator).
* Pregnant or breast-nursing women
* Patients who have active cardiac disease requiring therapy for failure, angina, arrythmia, or infarction within the preceding 6 months (exception: any patient whose cardiac failure is compensated on medications)
* Patients who have asthma
* Patients who have autoimmune disease such as inflammatory bowel disease, lupus erythematosus, ankylosing spondylitis, scleroderma, and multiple sclerosis
* Patients who have serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator)
* Patients who have other prior or concurrent malignancy except for in-situ-carcinoma of cervix or adequately treated basal cell carcinoma of skin.
* Patients who received chemotherapy, steroid or biologic treatment within 4 weeks prior to enrollment